Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice.
Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase 1 (IDO1) to evade immune control. Checkpoint inhibitors have demonstrated durable anti-tumor efficacy in human and preclinical...
Main Authors: | Timothy Affolter, Heather P Llewellyn, Derek W Bartlett, Qing Zong, Shuhua Xia, Vince Torti, Changhua Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0217276 |
Similar Items
-
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
by: Shuang Qin, et al.
Published: (2019-11-01) -
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
by: Hao Zhang, et al.
Published: (2021-06-01) -
Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01) -
Immune checkpoint PD-1/PD-L1 CTLA-4/CD80 are blocked by Rhus verniciflua stokes and its active compounds
by: Tae In Kim, et al.
Published: (2020-01-01)